General Information

[Guest guest]

Here is a message from Dr. Sawyers. Whether he is your doctor or not,

his knowledge about CML is undisputabily at the top of the heap. His thoughts

about cost becoming a factor in treatment is very interesting.

http://www.cancernetwork.com/hematologic-cancer/content/article/10165/1636076?pa\

geNumber=2 & GUID=8DC59E1F-1427-4EFF-AC52-DD957B592019 & rememberme=1#VantagePoint

_________________________________

A multi-institutional group of researchers have zeroed in on a more accurate way

to decipher treatment outcomes in young leukemia patients using information from

a simple complete blood count test.

http://www.cancernetwork.com/leukemia-lymphoma/content/article/10165/1570052

______________________________

Doctors (Oncologists) Will Flee Medicare's Low Payments, Onerous Rules

By Grace-Marie | August 13, 2010

The exodus of doctors from Medicare and likely from private practice altogether

- is accelerating. The signs are undeniable: A 2008 poll by an independent

Medicare commission found that 28 percent of seniors had trouble finding a

primary care doctor, up from 24 percent the year before.

http://www.searchmedica.com/resource.html?rurl=http%3A%2F%2Fwww.cancernetwork.co\

m%2Fall-content%2F & q=cml+-+August+2010 & c=on & ss=cancerNetworkLink & p=Convera & fr=tr\

ue & ds=0 & srid=1

___________________________________________

" Molecular responses continue to deepen over time, and there continue to be

fewer progression events and fewer deaths with nilotinib, " said ENESTnd lead

investigator A. Larson, MD, a professor of medicine and director of the

hematologic malignancies program at the University of Chicago. " Longer follow-up

supports nilotinib as a new standard of care in patients with newly diagnosed

CML. "

http://www.searchmedica.com/resource.html?rurl=http%3A%2F%2Fwww.cancernetwork.co\

m%2Fchronic-myeloid-leukemia%2Fmashuptool%2FMashupTool_INSTANCE_Nqff%2F1391%2Fmu\

ltiPage%2F1 & q=cml+-+August+2010 & c=on & ss=cancerNetworkLink & p=Convera & fr=true & ds=0\

& srid=3

_____________________________________

According to a duo of ASCO 2009 presentations, some patients are not being dose

escalated on imatinib prior to switching to dasatinib (Sprycel). Also, switching

to dasatinib was found to be associated with more adverse events than dose

escalation of imatinib. “These studies give us a window on real-world clinical

practice and suggest that we need to make greater efforts to educate patients

and providers on how to follow NCCN guidelines,” said the senior author of both

posters, , MD, director of medical oncology at Dana-Farber Cancer

Center and professor of medicine at Harvard Medical School, both in Boston.

http://www.cancernetwork.com/chronic-myeloid-leukemia/content/article/10165/1430\

990

___________________________

Chronic myeloid leukemia: an update of concepts and management recommendations

of European LeukemiaNet.

http://www.ncbi.nlm.nih.gov/pubmed/19884523

_________________________________

For the price of $50, you can log in and purchase the entire article. I don't

know how many takers they will have at that asking price, but I thought that

little teaser was certainly meant to garner your interest.

by Lev Osherovich, Senior Writer

Two American teams have identified new cancer stem cell–related targets in the

NOTCH pathway that determine progression of late-stage CML and AML. The findings

could help companies developing antagonists of NOTCH signaling, which has not

previously been considered a prime target in hematological malignancies.

http://www.nature.com/scibx/journal/v3/n32/full/scibx.2010.974.html

FYI,

Lottie Duthu

[Guest guest]

HI, Lottie: Many thanks for the useful info. you post on vitamins, organics,

etc.

MSKCC actually has an alternative medicine department that works in conjunction

with all the other departments.

They have a great website dealing with herbals and other types of alternative

medicines with actual scientific research. Very interesting......

Please see:

http://www.mskcc.org/mskcc/html/11570.cfm

Take care,

Carl